Pacific Biosciences of California Inc. (PACB)
PACB trades on Nasdaq in Industrials, Biotechnology: Laboratory Analytical Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1299130/000129913026000034/0001299130-26-000034-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PACB on Nasdaq |
| Sector | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| Country | United States |
| IPO year | 2010 |
| SEC CIK | 0001299130 |
| SEC industry code | Laboratory Analytical Instruments |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $160.0M |
| Net income | -$546.4M |
| Operating income | -$553.9M |
| Net margin | -341.5% |
| Operating margin | -346.2% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $63.7M |
| Total assets | $784.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.0× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-02-25 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-08-05 |
| Latest proxy | DEFA14A | 2026-05-22 |
Source: SEC EDGAR submissions feed, 970 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -26.8% |
| 1 month | +48.5% |
| 3 months | +33.6% |
| Year to date | +6.4% |
| 1 year | +22.8% |
| From 52-week high | -30.7% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Laboratory Analytical Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CTKB | Cytek Biosciences Inc. | $5.35 | +0.75% | $695.4M |
| EYPT | EyePoint Inc. | $3.07 | -7.53% | $264.7M |
| NAUT | Nautilus Biotechnology Inc. | $2.05 | -5.53% | $260.9M |
| LAB | Standard BioTools Inc. | $0.6589 | +0.17% | $260.0M |
| ALMR | Alamar Biosciences Inc. | $23.52 | -2.97% | $1.6B |
| QTRX | Quanterix Corporation | $3.15 | -0.32% | $149.0M |
| SEER | Seer Inc. | $2.11 | -1.86% | $116.8M |
| BRKR | Bruker Corporation | $56.19 | -0.11% | $8.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier